Cargando…

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors

Nivolumab is a fully human monoclonal antibody that inhibits programmed death‐1 activation. The clinical pharmacology profile of nivolumab was analyzed by a population pharmacokinetics model that assessed covariate effects on nivolumab concentrations in 1,895 patients who received 0.3–10.0 mg/kg niv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bajaj, G, Wang, X, Agrawal, S, Gupta, M, Roy, A, Feng, Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270302/ https://www.ncbi.nlm.nih.gov/pubmed/28019091 http://dx.doi.org/10.1002/psp4.12143

Ejemplares similares

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
por: Sanghavi, Kinjal, et al.
Publicado: (2019)

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer
por: Zhang, Jason, et al.
Publicado: (2019)

Quantitative Characterization of the Exposure–Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma
por: Wang, X, et al.
Publicado: (2016)

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
por: Lee, Keun‐Wook, et al.
Publicado: (2017)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
por: Gibiansky, Leonid, et al.
Publicado: (2022)

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
por: Tohi, Makiko, et al.
Publicado: (2023)

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
por: Ferron, Géraldine M., et al.
Publicado: (2013)

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
por: Lu, Yasong, et al.
Publicado: (2022)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
por: He, Jimmy, et al.
Publicado: (2022)

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors
por: Savelieva, Marina, et al.
Publicado: (2015)

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors
por: Lin, Swan, et al.
Publicado: (2019)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
por: Budha, Nageshwar, et al.
Publicado: (2022)

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2016)

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
por: Agrawal, Shruti, et al.
Publicado: (2015)

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
por: Zhao, X., et al.
Publicado: (2017)

Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors
por: Yang, Fen, et al.
Publicado: (2022)

Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors
por: Sheng, Jennifer, et al.
Publicado: (2021)

Preparation of Evodiamine Solid Dispersions and Its Pharmacokinetics
por: Xu, H., et al.
Publicado: (2011)

Pharmacokinetic study of aldoxorubicin in patients with solid tumors
por: Mita, Monica M., et al.
Publicado: (2014)

Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
por: Aregbe, Abdulateef O., et al.
Publicado: (2012)

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature
por: Pîrlog, Cristina-Florina, et al.
Publicado: (2022)

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
por: Zibelman, Matthew, et al.
Publicado: (2023)

Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors
por: Zhou, Xiaofei, et al.
Publicado: (2021)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors
por: Wang, R., et al.
Publicado: (2023)

Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
por: Sy, Sherwin K. B., et al.
Publicado: (2018)

Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
por: Gong, Xiaohua, et al.
Publicado: (2023)

Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis
por: Yamaguchi, Teppei, et al.
Publicado: (2021)

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
por: Schmidt, Keith T., et al.
Publicado: (2020)

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
por: Wang, Erjian, et al.
Publicado: (2021)

Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
por: Hong, David S., et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6u0ti6ts573opha70r3voo490v